0001437749-22-006190.txt : 20220314 0001437749-22-006190.hdr.sgml : 20220314 20220314194306 ACCESSION NUMBER: 0001437749-22-006190 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220303 FILED AS OF DATE: 20220314 DATE AS OF CHANGE: 20220314 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HUNT DOUGLAS M CENTRAL INDEX KEY: 0001727172 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35703 FILM NUMBER: 22738353 MAIL ADDRESS: STREET 1: C/O PUMA BIOTECHNOLOGY,INC. STREET 2: 10880 WILSHIRE BOULEVARD, SUITE 2150 CITY: LOS ANGELES STATE: CA ZIP: 90024 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PUMA BIOTECHNOLOGY, INC. CENTRAL INDEX KEY: 0001401667 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770683487 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10880 WILSHIRE BLVD. STREET 2: SUITE 2150 CITY: LOS ANGELES STATE: CA ZIP: 90024 BUSINESS PHONE: (424) 248-6500 MAIL ADDRESS: STREET 1: 10880 WILSHIRE BLVD. STREET 2: SUITE 2150 CITY: LOS ANGELES STATE: CA ZIP: 90024 FORMER COMPANY: FORMER CONFORMED NAME: INNOVATIVE ACQUISITIONS CORP DATE OF NAME CHANGE: 20070601 4 1 rdgdoc.xml FORM 4 X0306 4 2022-03-03 0001401667 PUMA BIOTECHNOLOGY, INC. PBYI 0001727172 HUNT DOUGLAS M C/O PUMA BIOTECHNOLOGY, INC. 10880 WILSHIRE BLVD., SUITE 2150 LOS ANGELES CA 90024 1 See Remarks Common Stock 2022-03-03 4 A 0 22647 0 A 82751 D Stock Option (Right to Buy) 2.33 2022-03-03 4 A 0 32353 0 A 2032-03-02 Common Stock 32353 32353 D Subject to the Grantee's continued service with the Company through the applicable vesting date, the Restricted Stock Units shall vest with respect to one-fourth (1/4th) of the Restricted Stock Units on each of July 1, 2022, January 1, 2023, July 1, 2023 and January 1, 2024. Subject to the Optionee's continued service with the Company through the applicable vesting date, the Option shall vest and become exercisable with respect to one-fourth (1/4th) of the Shares subject thereto on each of July 1, 2022, January 1, 2023, July 1, 2023 and January 1, 2024. The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer. /s/ Douglas M. Hunt 2022-03-14